Alcoholic liver damage
Conditions
Interventions
Liver pure tablet group:Oral liver tablets for 30 days Abstinence from alcohol, 3 times a day, 2 tablets each time
Placebo group:Oral liver pure tablets placebo for 30 days Abstinence from alcohol, 2 tablets 3 times a day
Sponsors
High-tech Hospital of the First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age 18-65 years old (inclusive), gender is not limited; 2.Meet the diagnostic criteria of the Guidelines for the Prevention and Treatment of Alcoholic Liver Disease (2018 Update): Long-term alcohol consumption history (usually more than 5 years), equivalent to ethanol levels >= 40 g/d for men and 20 g/d for women >=; or a history of heavy alcohol consumption within 2 weeks, equivalent to an ethanol amount > 80 g/d. Ethanol content (g) = alcohol consumption (mL) × ethanol content (%) × 0.8; Clinical symptoms are non-specific, may be asymptomatic, and may include right upper quadrant pain, fatigue, nausea, vomiting, loss of appetite, etc.; Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or ?-glutamyltransferase (GGT) are elevated; 3.There is an abnormality in the lipid index (TC, TG, LDL-C, HDL-C); 4.Previous examinations suggested fatty liver and was diagnosed as fatty liver by liver transient elastography; 5.Willing to obey the doctor's intervention plan and cooperate with follow-up, informed consent and sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Patients with various types of viral hepatitis, autoimmune liver disease, drug-induced liver injury, vascular liver disease, genetic metabolic liver disease, or primary liver cancer; 2.Individuals with serious diseases of important organs such as cardiovascular, lung, liver, and kidney diseases, or patients with diabetes, severe thyroid disease, metabolic diseases, malignant tumors, or severe immune system diseases; 3.Patients who are unable to abstain from alcohol during the study; 4.Known allergy or contraindication to any component of the study drug; 5.Those who have taken other drugs or therapies related to the efficacy of the treatment of this disease within 3 months, those who have lost weight or participated in other interventional clinical experiments; 6.Pregnancy, lactation, and having a birth plan during the trial period; 7.Other conditions that the investigator deems unsuitable for participation in the study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical improvement is effective; | — |
Secondary
| Measure | Time frame |
|---|---|
| Indicators of liver function;Blood lipid indicators;Clinical symptom score;BMI;Liver stiffness and degree of hepatic steatosis; | — |
Countries
China
Contacts
Public ContactZeng Hao
High-tech Hospital of the First Affiliated Hospital of Nanchang University
Outcome results
None listed